New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
10:35 EDTALXNAlexion says data confirm long-term safety, efficacy of chronic Soliris therapy
Alexion Pharmaceuticals announced the presentation of new data demonstrating the long-term benefits of Soliris in patients with paroxysmal nocturnal hemoglobinuria, a debilitating, ultra-rare and life-threatening blood disorder. Data including the clinical benefits of Soliris in the treatment of patients with PNH and atypical hemolytic uremic syndrome were presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta. The company said ten-year data from a large cohort of patients with PNH from the United Kingdom confirm the long-term safety and efficacy of chronic Soliris therapy and demonstrate the impact of Soliris on quality of life. The long-term safety of Soliris was also demonstrated in PNH clinical development trials in which patients were treated continuously with Soliris and followed for up to 5.5 years and other Soliris data was presented as well.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
09:26 EDTALXNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:02 EDTALXNAlexion resumed with an Outperform at Leerink
Subscribe for More Information
February 4, 2016
07:40 EDTALXNAlexion guidance conservative, says Oppenheimer
Subscribe for More Information
07:32 EDTALXNAlexion shares should be bought aggressively, says SunTrust
Subscribe for More Information
07:26 EDTALXNAlexion weakness a buying opportunity, says Brean Capital
Subscribe for More Information
February 3, 2016
09:19 EDTALXNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
06:36 EDTALXNAlexion reports Q4 non-GAAP EPS $1.13, consensus $1.10
Subscribe for More Information
06:33 EDTALXNAlexion sees FY16 EPS $5.00-$5.20, consensus $5.53
Subscribe for More Information
February 2, 2016
14:32 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use